Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943594 | 0.85 | GRM2 (1.00) | GRM2 | |
| SCHEMBL4940249 | 0.84 | GRM2 (1.00) | GRM2 | |
| SCHEMBL4944338 | 0.83 | GRM2 (1.00) | GRM2 | |
| SCHEMBL4945443 | 0.83 | GRM2 (0.78) | GRM2 | |
| SCHEMBL4943539 | 0.83 | GRM2 (0.81) | GRM2 | |
| SCHEMBL4944421 | 0.81 | GRM2 (0.74) | GRM2 | |
| SCHEMBL4937161 | 0.80 | GRM2 (0.67) | GRM2 | |
| SCHEMBL18472945 | 0.80 | GRM2 (0.76) | GRM2 | |
| SCHEMBL25289260 | 0.80 | GRM2 (0.71) | GRM2 | |
| SCHEMBL4946414 | 0.80 | GRM2 (0.71) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | claimed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-10377695-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-12 | — | — | US | disclosed |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-12 | — | — | US | disclosed |
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | disclosed |
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | disclosed |
| WO-2015157187-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | GRM3, GRM2, GRM1 | GRM2 2/4885 |
| US-10377695-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | GRM3, GRM2, GRM1 | GRM2 2/4885 |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | GRM2 1/4885 |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | GRM3, GRM2, GRM1 | GRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.